Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review

Evelyne Roets, Winette van der Graaf, Bauke H.G. van Riet, Rick L. Haas, Eugenie Younger, Francesco Sparano, Roger Wilson, Stevie van der Mierden, Neeltje Steeghs, Fabio Efficace, Olga Husson*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

9 Downloads (Pure)

Abstract

Background: 

This systematic review evaluates reporting of patient-reported outcomes (PROs) within randomized clinical trials (RCTs) for advanced soft tissue sarcoma (STS) patients. 

Methods: 

A systematic literature search from January 2000 – August 2022 was conducted for phase II/III RCTs evaluating systemic treatments in adult patients with advanced STS. Quality of PRO reporting was assessed using the CONSORT PRO extension. 

Results: 

Out of 7294 abstracts, 59 articles were included; comprising 43 RCTs. Only 15 RCTs (35%) included PROs, none as primary endpoints. Only 10 of these RCTs reported PROs, either in the primary (6/10) or secondary publication (1/10) or in both (3/10), with a median time interval of 23 months. The median CONSORT PRO adherence score was 5.5/14, with higher scores in publications focusing exclusively on PROs. 

Conclusion: 

These results highlight the need for improved and more consistent PRO reporting to inform patient care in the setting of advanced STS.

Original languageEnglish
Article number104345
JournalCritical Reviews in Oncology/Hematology
Volume197
DOIs
Publication statusPublished - May 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors

Fingerprint

Dive into the research topics of 'Patient-reported outcomes in randomized clinical trials of systemic therapy for advanced soft tissue sarcomas in adults: A systematic review'. Together they form a unique fingerprint.

Cite this